Biogen

BIIB

Market cap $28.2B

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Biogen Inc. (BIIB) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript

Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new Chair Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new Chair

Biogen Inc. (NASDAQ: BIIB) on Friday reported better-than-expected fourth-quarter earnings.

Biogen (BIIB) is transitioning from a shrinking MS franchise to a portfolio anchored in rare disease and Alzheimer's therapies, driving improved mix quality. BIIB's 2025 growth products generated $3.3B, offsetting MS declines; non-GAAP EPS exceeded guidance at $15.28, reflecting strong cost discipline and operational execution. Despite a guided mid-single-digit revenue decline in 2026, BIIB maintains robust earnings power, with key catalysts, including Leqembi expansion and potential high-dose Spinraza approval.

The biotech published its last set of financials for 2025. Its quarterly revenue and adjusted profitability declined, yet both still topped the consensus analyst estimates.

Biogen Inc. (BIIB) Q4 2025 Earnings Call Transcript

Biogen tops Q4 earnings and sales estimates, and shares rise after the company issues an encouraging 2026 adjusted EPS outlook despite revenue pressure.

The headline numbers for Biogen (BIIB) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.